ProBioGen in biosimilar deal with Bio Farma Indonesia

Dr Iskandar, President Director of Bio Farma (right) and Dr Wieland Wolf, CEO of ProBioGen (left)

Trastuzumab development and transfer for first Indonesian on-site production.

The turn-key process, including state-of-the-art analytics, will then be transferred to Indonesia to enable local market production. The agreement is fee-for-service based, license and royalty-free.

Dr Wieland Wolf, ProBioGen’s CEO commented: “This is the 1st Trastuzumab molecule which will be produced locally for the Indonesian market to provide effective modern medicines for a country of 250 million people. We are proud to be a partner of the well-established and experienced Bio Farma, a government company with a successful history of more than 120 years.”

Dr Gabriele Schneider, Vice President Business Development of ProBioGen added: “The task to develop high-quality therapeutic proteins with high productivity but low commercial-scale production costs fits very well to our passion for developing intelligent biopharmaceutical solutions, based on our in-house CHO manufacturing platform of adapted cells, robust and economical process development know-how and chemically defined media platform.”

Dr Iskandar, President Director of Bio Farma stated “Bio Farma is proud to be collaborating with ProBioGen. This collaboration will undoubtedly enhance our vision to enter lifes cience industry, where in future it will contribute to producing high-quality biopharmaceuticals particularly for the Indonesian people and others in the world.”